Peringatan Keamanan

There is no information regarding the acute toxicity (LD50) and overdose of nemolizumab.L51159

Nemolizumab

DB15252

biotech approved investigational

Deskripsi

Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),L51159 which is an endogenous cytokine implicated in the pathophysiology of various skin inflammatory disorders.A264254 By binding to IL-31RA, nemolizumab blocks the IL-31 signalling cascades that lead to inflammation.L51159 Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.A264274 It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.L51169

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The estimated terminal elimination half-life (SD) of nemolizumab is 18.9 (4.96) days.[L51159]
Volume Distribusi The estimated volume of distribution is 7.67 L.[L51159]
Klirens (Clearance) The estimated systemic clearance is 0.263 L/day.[L51159]

Absorpsi

After a single dose, nemolizumab exposure increased dose proportionally over a dose range of 0.03 and 3 mg/kg following subcutaneous administration. After multiple doses, drug systemic exposure increased in an approximately dose-proportional manner across the subcutaneous dose range up to 30 mg. There was a decrease in bioavailability by 9% with the 60 mg subcutaneous dose and by 15% with the 90 mg subcutaneous dose.L51159 Following multiple doses of nemolizumab in subjects with prurigo nodularis, the estimated mean (SD) steadystate trough concentrations of nemolizumab were 3.04 (1.23) µg/mL in subjects with bodyweight less than 90 kg; and 3.66 (1.63) µg/mL in subjects with bodyweight of 90 kg or more. Steady state nemolizumab concentrations were achieved by week four in subjects weighting less than 90 kg and by week 12 in subjects weighing 90 kg or more. Following an initial subcutaneous dose of 60 mg, nemolizumab reached peak mean (SD) concentrations (Cmax) of 7.5 (2.31) µg/mL by approximately six days post-dose.L51159

Metabolisme

The metabolic pathway of nemolizumab has not been characterized. In the same manner as endogenous IgG, nemolizumab is expected to be degraded into small peptides by catabolic pathways.L51159

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Nemolizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Nemolizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Nemolizumab.
Estrone Estrone may increase the thrombogenic activities of Nemolizumab.
Estradiol Estradiol may increase the thrombogenic activities of Nemolizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Nemolizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Nemolizumab.
Mestranol Mestranol may increase the thrombogenic activities of Nemolizumab.
Estriol Estriol may increase the thrombogenic activities of Nemolizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Nemolizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Nemolizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Nemolizumab.
Tibolone Tibolone may increase the thrombogenic activities of Nemolizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Nemolizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Nemolizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Nemolizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Nemolizumab.
Zeranol Zeranol may increase the thrombogenic activities of Nemolizumab.
Equol Equol may increase the thrombogenic activities of Nemolizumab.
Promestriene Promestriene may increase the thrombogenic activities of Nemolizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Nemolizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Nemolizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Nemolizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Nemolizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Nemolizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Nemolizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Nemolizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Nemolizumab.
Formononetin Formononetin may increase the thrombogenic activities of Nemolizumab.
Estetrol Estetrol may increase the thrombogenic activities of Nemolizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Nemolizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nemolizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Nemolizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Nemolizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Nemolizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nemolizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nemolizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Nemolizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nemolizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Nemolizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Nemolizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Nemolizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nemolizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nemolizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Nemolizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nemolizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nemolizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Nemolizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nemolizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Nemolizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Nemolizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Nemolizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nemolizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nemolizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Nemolizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Nemolizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Nemolizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Nemolizumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Nemolizumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Nemolizumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Nemolizumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Nemolizumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Nemolizumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Nemolizumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Nemolizumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Nemolizumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Nemolizumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Nemolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Nemolizumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Nemolizumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Nemolizumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Nemolizumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Nemolizumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Nemolizumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Nemolizumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Nemolizumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Nemolizumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Nemolizumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Nemolizumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Nemolizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Nemolizumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Nemolizumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Nemolizumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Nemolizumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Nemolizumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Nemolizumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Nemolizumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nemolizumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Nemolizumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Nemolizumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Nemolizumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Nemolizumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Nemolizumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Nemolizumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Nemolizumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Nemolizumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Nemolizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Nemolizumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Nemolizumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Nemolizumab.

Target Protein

Interleukin-31 receptor subunit alpha IL31RA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 33629401
    Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J: Interleukin-31: The "itchy" cytokine in inflammation and therapy. Allergy. 2021 Oct;76(10):2982-2997. doi: 10.1111/all.14791. Epub 2021 Mar 16.
  • PMID: 35412530
    Labib A, Vander Does A, Yosipovitch G: Nemolizumab for atopic dermatitis. Drugs Today (Barc). 2022 Apr;58(4):159-173. doi: 10.1358/dot.2022.58.4.3378056.
  • PMID: 35766128
    Stander S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A, Chaouche K, Ahmad F, Piketty C: Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1820-1825. doi: 10.1111/jdv.18377. Epub 2022 Jul 4.
  • PMID: 37888917
    Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Stander S: Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
  • PMID: 35834124
    Keam SJ: Nemolizumab: First Approval. Drugs. 2022 Jul;82(10):1143-1150. doi: 10.1007/s40265-022-01741-z. Epub 2022 Jul 14.
  • PMID: 16461142
    Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B: IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006 Feb;117(2):411-7. doi: 10.1016/j.jaci.2005.10.033.
  • PMID: 29366565
    Bagci IS, Ruzicka T: IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018 Mar;141(3):858-866. doi: 10.1016/j.jaci.2017.10.045. Epub 2018 Feb 1.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Nemluvio
    Injection, powder, lyophilized, for solution • 30 mg/100mg • Subcutaneous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul